Management of non small cell lung cancer

##plugins.themes.academic_pro.article.sidebar##

Published Dec 7, 2012
Download
pdf
Vol. 90 No. 12 (2012): Issue Dec 2012

##plugins.themes.academic_pro.article.main##

Besma Ourari-Dhahri
Hédi Ben Slima
Jihen Ben Amar
Leila El Gharbi
Mohamed Ali
Baccar Saloua Azzabi
Hichem Aouina
Hend Bouacha

Abstract

Background : The broncopulmonary cancer is a major problem of public health whose diagnosis is most of the time unfavorable. For a long time, strategies of management of cancer have not taken into consideration much the histological type and few authors have studied the implication of histological type of cancer on the future of patients having cancer.
Aim: Taking into account the results of recent studies, we propose to review the recent epidemiological and biological aspects of  bronchial cancers and then to study the impact on the therapeutic strategy.
Methods: Review of literature
Results: The scientific progress and the discovery of new mechanisms of carcinogenesis considerably enlarge the therapeutic potential targets and enable to adopt a more specific approach of the cancer cell.
Conclusion: Despite the progress observed in thoracic cancerology, the benefits concerning survival remain modest. The oncoming of new molecules specifically targeting a stage of oncogenesis enables a better therapeutic selectivity and a lesser toxicity.

Keywords:

Lung cancer, histology, treatment, outcomes

##plugins.themes.academic_pro.article.details##

References

  1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours, pathology and genetics: tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004.
  2. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology,pathology and patterns of care Lung Cancer 2007;57:253-60
  3. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male, female differences diminishing adenocarcinoma rising. Int J Cancer 2005 ;117:294- 9.
  4. Blanchon F, Grivaux M, Collon T, et al. Epidemiologic of primary bronchial carcinoma management in the general French hospital centers. Rev Mal Resp 2002;19 :727-34
  5. Mc Donels Sivers AL, Nimri CF, Stoner GD, et al. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002; 8:1127-38.
  6. Mc Donels Sivers AL, Stoner GD, Lubet RA, et al. Differential expression of criticalncellular genes in human lung carcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia 2002; 4:141-50
  7. Wang T, Hopkins D, Shmidt C, et al. Identification of genes differentially over -expressed in lung squamous cell carcinoma using combination of c DNA substraction and microarray analysis. Oncogene 2000;19:1519-28
  8. Liu Y, Sun W, Zhang K et al. Identification of genes differentially expressed in human primary lung sqamous cell carcinoma. Lung Cancer 2007:56:307-17
  9. Weir BA, Woo MS, Getz G, et al. Charactering the cancer genome in lung adenocarcima. Nature 2007; 450:893-98.
  10. Eberhard DA, Giaccone G, Johnson BE. Non-small-Cell Lung Cancer Working group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non Small Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-94.
  11. Salvatierra A, Biamonde C, Llamas JM et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990;97: 1052-58.
  12. Ferrigno D, Buccheri G. Cranial Computed tomography as a part of the initial staging procedures for patients with non small cell lung cancer. Chest 1994; 106: 1025-29.
  13. French National Federation of Cancer Centers (FNCLCC).Standards Options on Recommendations (SOR) for the perioperative treatment of patients with resectable non-small cell lung cancer. Rev Mal Respir 2007; 24: 1049-64.
  14. Barlesi F, Barrau K, Doddoli C, et al. Phase III randomized trial of chemotherapy with cisplatine plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective. Rev Mal Respir 2006; 23:489-96.
  15. Kim TY, Yang SH, Lee SH, et al A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small lung cancer Am J Clin Oncol 2002 ;25:238- 43.
  16. Huang EH, Liao Z, Cox JD et al. Comparison of Outcomes for patients with unresecable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs.concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007;68: 779-85.
  17. Scagliotti GV, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus premetrexed in chemotherapy-naïve patients with -advancedstage non-small-cell lung cancer .J Clin Oncol 2008;26:3543-51.
  18. Johnson DH, Fehrenbacher L, Novoty WF et al. Randomized phase II trial comparing bevacizumab plus premetrexed and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or locally advanced or metastatic nonsmall- cell lung cancer. J Clin Oncol 2004;22: 2184-91.
  19. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med 2006;355: 2542-50.
  20. Manegold C, von Pawel J, Zatloukal P et al. BO17704(AVAIL):A Phase III Randomised Study Of First-Line Bevacizumab Combined With Cancer (NSCLC).Ann Oncol 2008;19(Supplement 8):vii1-vii4.Cisplatin/Gemcitabine (Cg)In Patients (Pts) With Advanced Or Recurrent Non-Squamous, Non -Small Cell Lung
  21. Sonia JC. Discussion LBA1, ESMO congress, Stockholm 2008.
  22. Pirker R, Szczesna A, Von Pawel J, et al. FLEX: A randomized,multicenter, phase III study of cétuximab in combination with cisplatin/Vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; ASCO Annual Meeting Proceeding26: Abstract 3.
  23. Scaglotti G, Hanna N, Fossella F, et al. The differential efficacy of permetexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009. 14(3):253-63.
  24. Clark GM, Zborowski D, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit fromerlotinib for patients with non-small cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR21.Clin Cancer Res 2006.7:389-94.
  25. Bossard N, Velten M, Remontet L, et al. Survie des patients atteints de cancer en France: principaux résultats de la première étude du réseau des registres français des cancers (Francim). Oncologie .2007; 9: 574-80.